Startups
Xylyx Bio is disrupting the organ transplant paradigm by bringing first-in-class human organ grafts to patients to expand the supply of transplantable organs for life-saving clinical transplantation and lower costs for treating end-stage disease.
Overview
Location
United States
Total raised
$3M
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 2, 2021 | Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute | BROOKLYN, N.Y., Sept. 2, 2021 /PRNewswire/ -- Xylyx Bio, Inc., a biotechnology company developing groundbreaking solutions for drug discovery and tissue modeling and repair, announced today that it has been awarded a Small Business Innovati... |
| Sep 1, 2021 | Xylyx Bio partners with Inventia Life Science to develop tissue-specific, digitally-printed bioinks for drug discovery | NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results de... |
Reviews 0
FAQ about Xylyx Bio
How much funding has Xylyx Bio raised?
Xylyx Bio has raised $3M in total across 1 funding round.
What has the press written about Xylyx Bio?
Parsers VC has collected 3 articles mentioning Xylyx Bio, among them “Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute” (Sep 2, 2021) and “Xylyx Bio partners with Inventia Life Science to develop tissue-specific, digitally-printed bioinks for drug discovery” (Sep 1, 2021).
Is Xylyx Bio still active?
Yes, Xylyx Bio is active; its latest activity on Parsers VC dates from Oct 20, 2026.